Drug approved for inherited blood disorder

(HealthDay)—Exjade (deferasirox) has been approved by the U.S. Food and Drug Administration to remove excess iron in the blood among people with a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT).

Too much iron in the blood can damage vital organs, the agency said Wednesday in a news release.

Thalassemia typically leads to the production of fewer and less hemoglobin, a protein that carries oxygen throughout the body. NTDT is a milder form of thalassemia that unlike other forms, does not require frequent blood transfusions. Thalassemia affects about 1,000 people in the United States, the FDA said.

The FDA previously approved Exjade to treat chronic iron overload among people who require blood transfusions.

The drug is produced by Novartis, East Hanover, N.J.

More information: The U.S. National Heart Lung and Blood Institute has more about thalassemia.

More Information

Related Stories

Blood protein offers help against anemia

date Jan 26, 2010

A new study shows that a protein found in blood alleviates anemia, a condition in which the body's tissues don't get enough oxygen from the blood. In this animal study, injections of the protein, known as transferrin, also ...

MIT uncovers key blood protein

date Oct 11, 2007

Scientists working in the only lab at MIT doing hematology research have uncovered a protein that plays a key role in the recycling of iron from blood.

Recommended for you

US appeals court upholds delay in Alzheimer's drug swap

date May 22, 2015

A federal appeals court has rejected a drug manufacturer's appeal and affirmed a judge's order that Actavis PLC keep distributing its widely used Alzheimer's medication until after its patent expires this summer.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.